Trial Profile
Randomized, Double-blind Placebo-controlled Clinical Study to Assess Safety, Tolerance, Pharmacokinetics, Pharmacodynamic of multiple-dose Kukoamine B Mesilate in Sepsis Patients
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 Jun 2023
Price :
$35
*
At a glance
- Drugs Kukoamine B (Primary)
- Indications Sepsis
- Focus Adverse reactions
- Sponsors Tianjin Chase Sun Pharmaceutical
- 01 Aug 2023 Results assessing the safety, tolerability, pharmacokinetics, and efficacy of kukoamine B (KB), an alkaloid compound with high affinity for both lipopolysaccharide (LPS) and oligodeoxynucle-otides containing CpG motifs (CpG DNA), in patients with sepsis-induced organ failure, published in the Journal of Critical Care.
- 19 Jan 2020 Status changed from recruiting to completed.
- 11 Apr 2019 Planned End Date changed from 31 Dec 2018 to 31 Dec 2019.